Background In the TOPAZ-1, patients with biliary tract cancers (BTC) and recurrence within 6 months after surgery were excluded, even if this event is frequently observed in clinical practice. Our study aimed to assess if the efficacy of cisplatin-gemcitabine-durvalumab (CGD) in this population is comparable to that reported in the phase 3 trial. Methods The study cohort included patients with BTC who underwent surgery on the primary tumor, experienced disease recurrence occurring <= 6 months or >6 months after surgery or after the end of adjuvant therapy and started CGD. The primary objectives were overall survival (OS) and progression free survival (PFS). Results A total of 178 patients were enrolled. No significant differences were observed between early and late relapse groups in OS (23.4 months vs not reached; HR 1.26; 95% CI, 0.67-2.37; P = .45) and PFS [7.0 months vs 9.8 months; HR 1.3(95% CI, 0.9-2.1) P = .13]. Overall response rate and disease control rate (P = .33 and P = .62) were comparable between the 2 groups, as the overall safety profile. In addition, we compared survival outcomes between the selected population and a historical cohort of patients with BTC treated with cisplatin-gemcitabine (CG) and found that despite the absence of statistical significance, CGD showed an outcome trend compared with CG regardless of the time of recurrence after surgery or adjuvant chemotherapy [(CG <= 6 vs CGD <= 6 months: HR 0.59, 95%CI, 0.35-1.01, P = .05; HR 0.70; 95%CI, 0.46-1.06, P = .09, OS and PFS, respectively) and (CG > 6 vs. CGD > 6 months: HR 0.50; 95%CI, 0.29-0.88, P = 0.0165; HR 0.54; 95%CI, 0.35-0.84, P = .0068, OS and PFS, respectively)]. Conclusion Our analysis suggests that CGD retains its efficacy independently of the timing of relapse after surgery or completion of adjuvant treatment in patients with advanced BTC.

Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population / Lo Prinzi, Federica; Salani, Francesca; Rimini, Margherita; Rizzato, Mario Domenico; Antonuzzo, Lorenzo; Camera, Silvia; Satake, Tomoyuki; Vandeputte, Hanne; Vivaldi, Caterina; Pressiani, Tiziana; Lucchetti, Jessica; Kim, Jin Won; Abidoye, Oluseyi; Rapposelli, Ilario Giovanni; Tamberi, Stefano; Finkelmeier, Fabian; Giordano, Guido; Pircher, Chiara; Chon, Hong Jae; Braconi, Chiara; Pastorino, Alessandro; Castet, Florian; Tamburini, Emiliano; Yoo, Changhoon; Parisi, Alessandro; Diana, Anna; Scartozzi, Mario; Prager, Gerald W; Avallone, Antonio; Schirripa, Marta; Kim, Il Hwan; Perkhofer, Lukas; Oneda, Ester; Verrico, Monica; Adeva, Jorge; Chan, Stephen L; Spinelli, Gian Paolo; Personeni, Nicola; Garajova, Ingrid; Rodriquenz, Maria Grazia; Leo, Silvana; Melo Alvim, Cecilia; Roque, Ricardo; Fornaro, Lorenzo; De Rosa, Antonio; Lavacchi, Daniele; Rossari, Federico; Ikeda, Masafumi; Dekervel, Jeroen; Niger, Monica; Balsano, Rita; Tonini, Giuseppe; Kang, Minsu; Bekaii-Saab, Tanios; Viola, Massimo Giuseppe; Silvestro, Lucrezia; Esposito, Luca; Boccaccino, Alessandra; Himmelsbach, Vera; Landriscina, Matteo; Ahcene Djaballah, Selma; Zanuso, Valentina; Masi, Gianluca; Lonardi, Sara; Rimassa, Lorenza; Casadei-Gardini, Andrea. - In: THE ONCOLOGIST. - ISSN 1083-7159. - (2024). [Epub ahead of print] [10.1093/oncolo/oyae256]

Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population

Parisi, Alessandro
Membro del Collaboration Group
;
2024-01-01

Abstract

Background In the TOPAZ-1, patients with biliary tract cancers (BTC) and recurrence within 6 months after surgery were excluded, even if this event is frequently observed in clinical practice. Our study aimed to assess if the efficacy of cisplatin-gemcitabine-durvalumab (CGD) in this population is comparable to that reported in the phase 3 trial. Methods The study cohort included patients with BTC who underwent surgery on the primary tumor, experienced disease recurrence occurring <= 6 months or >6 months after surgery or after the end of adjuvant therapy and started CGD. The primary objectives were overall survival (OS) and progression free survival (PFS). Results A total of 178 patients were enrolled. No significant differences were observed between early and late relapse groups in OS (23.4 months vs not reached; HR 1.26; 95% CI, 0.67-2.37; P = .45) and PFS [7.0 months vs 9.8 months; HR 1.3(95% CI, 0.9-2.1) P = .13]. Overall response rate and disease control rate (P = .33 and P = .62) were comparable between the 2 groups, as the overall safety profile. In addition, we compared survival outcomes between the selected population and a historical cohort of patients with BTC treated with cisplatin-gemcitabine (CG) and found that despite the absence of statistical significance, CGD showed an outcome trend compared with CG regardless of the time of recurrence after surgery or adjuvant chemotherapy [(CG <= 6 vs CGD <= 6 months: HR 0.59, 95%CI, 0.35-1.01, P = .05; HR 0.70; 95%CI, 0.46-1.06, P = .09, OS and PFS, respectively) and (CG > 6 vs. CGD > 6 months: HR 0.50; 95%CI, 0.29-0.88, P = 0.0165; HR 0.54; 95%CI, 0.35-0.84, P = .0068, OS and PFS, respectively)]. Conclusion Our analysis suggests that CGD retains its efficacy independently of the timing of relapse after surgery or completion of adjuvant treatment in patients with advanced BTC.
2024
File in questo prodotto:
File Dimensione Formato  
Lo Prinzi_Effcacy-cisplatin-gemcitabine-durvalumab_2024.pdf

Solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza d'uso: Creative commons
Dimensione 991.79 kB
Formato Adobe PDF
991.79 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/339217
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact